MEDICAL equipment manufacturer Vernacare is playing a leading role in the roll-out of the Covid-19 vaccination.
The Bolton-based firm is providing the specialist needles needed to deliver the jab and together with healthcare firm Hospidex NV delivered a 100 million ‘low dead space needles’ to Germany.
This is the second time the town centre company has helped in the fight against the virus.
Early on in the pandemic it worked round-the-clock to provide hospitals with the infection control products needed.
The specialist injection needles (pictured) are said to deliver a more effective vaccination roll-out as they extract more doses per vial — and can help bring a faster resolution to the pandemic.
In recent months the firm has developed a highly compatible low dead space needle solution and the company has designed and adapted their low dead space needles to fit the great majority of leading syringe brands.
BioNTech has purchased more than 150 million needles from Vernacare and is in discussions to purchase more. It is making these needles available to countries around the world to those who need them.
(Shipment of needles)
James Steele, chief executive officer of Vernacare, said: “Vernacare is ready and positioned to play its part in responding to and managing the Covid-19 pandemic situation.”
Vernacare will run with a production capacity of over one billion low dead space needles per year, ready to respond to the ongoing and evolving Covid-19 pandemic and vaccination roll out programmes.
The company (pictured) says health authorities, governments, and vaccine manufacturers now universally recognise the importance of low dead space equipment in maximising dosage capability and that low dead space needles are a fast and efficient solution.
The Bolton outfit and its long term trading partner Hospidex NV, headquartered in Belgium, has gained a leading position in the European Union Covid-19 tender and is actively fielding enquiries from European governments as vaccination programmes are ramped up.
Since the pandemic began, Vernacare ramped up its production and it has now increased to 60 per cent more than normal to keep up with demand from around the world for infection control products.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here